All In Biotech

Drug Trial Radar · NCT07937852

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)

A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Jan 18, 2027

Primary completion

Nov 30, 2029

Study completion Nov 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).

Conditions

  • Multiple Sclerosis

Interventions

  • FenebrutinibDrug

    Fenebrutinib will be administered as per the schedule specified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.